Cellectis S.A. (NASDAQ:CLLS) Short Interest Update

Key Points

• Short interest surged 68.5% to 488,061 shares as of September 15, representing 0.6% of shares outstanding and 2.4 days of average trading volume.
• Cellectis shares traded at $1.50, near their 52-week low of $1.25, while the company reported a quarterly loss of $0.22 per share and revenue of $6.9 million, below analyst expectations.
• Analyst sentiment is mixed but leans cautious: Cellectis has a consensus “Hold” rating, with an average price target of $5.46 after several firms cut ratings or targets.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 488,061 shares, an increase of 68.5% from the August 31st total of 289,689 shares. Based on an average trading volume of 207,376 shares, the short-interest ratio is presently 2.4 days. Currently, 0.6% of the shares of the company are short sold.

Cellectis Price Performance

Shares of Cellectis stock traded up $0.03 on Wednesday, hitting $1.50. 6,198 shares of the company traded hands, compared to its average volume of 52,967. Cellectis has a 52 week low of $1.25 and a 52 week high of $5.48. The business has a 50-day simple moving average of $2.70 and a 200 day simple moving average of $3.16. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37. The stock has a market capitalization of $150.51 million, a P/E ratio of -2.31 and a beta of 2.92.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. The firm had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cellectis stock. Lido Advisors LLC bought a new stake in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,094 shares of the biotechnology company's stock, valued at approximately $32,000. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CLLS has been the subject of a number of recent analyst reports. Weiss Ratings lowered shares of Cellectis from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, September 16th. Barclays downgraded shares of Cellectis from an "overweight" rating to an "underweight" rating and decreased their price objective for the company from $9.00 to $1.30 in a research report on Wednesday, September 16th. Wells Fargo & Company dropped their target price on shares of Cellectis from $4.00 to $3.00 and set an "equal weight" rating for the company in a report on Tuesday, September 15th. Citizens Jmp reiterated a "market perform" rating on shares of Cellectis in a research note on Tuesday, September 15th. Finally, Robert W. Baird decreased their price target on Cellectis from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cellectis presently has a consensus rating of "Hold" and an average target price of $5.46.

About Cellectis

Cellectis SA NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis' product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.